4 key updates in biologics for spine

Written by Alan Condon | June 13, 2019 | Print  |

Here are four key updates in about spinal biologics companies and advancements.

1. NC Biomatrix BV is producing a biomaterial that will assist the treatment of intervertebral disc degeneration in a minimally invasive way. It is a cell-driven matrix gel that can be injected into the spinal disc and repair disc volume and height, easing pain in patients suffering from degenerative disc disease.

2. Ottawa, Canada-based biomaterials startup Spiderwort closed a $500,000 funding round. The company's biomaterials were developed to treat spinal cord injuries and soft tissue regeneration in clinical trials.

3. Selby Chen, MD, assistant professor of neurosurgery at the Mayo Clinic in Jacksonville, Fla., discussed the importance of finding alternatives to spinal fusions, including biologic and biophysical treatments for degenerative disc disease.

4. Niagara Falls (N.Y.) Memorial Medical Center and Andrew Cappuccino, MD, of Buffalo (N.Y.) Spine Surgery are opening a stem cell therapy center to treat patients suffering from spine pain and orthopedic conditions.

More articles on biolgics:
California stem cell clinic scrutinized — 5 insights
Biomatrix develops minimally invasive biomaterial to treat intervertebral disc degeneration
Biomaterials startup raises $500K for scaffolds to treat spinal cord injuries

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies here.

Top 40 Articles from the Past 6 Months